This 2.7%-Yielding Dividend King Remains One of the Healthiest Income Stocks You Can Buy

Johnson & Johnson reported robust third-quarter results, with sales up 7% to $24 billion and adjusted net income rising 16% to $6.8 billion, supported by strong free cash flow and a AAA-rated balance sheet. The company raised its full-year sales outlook and maintained its EPS growth forecast, while announcing plans to separate its orthopedics business to sharpen focus on high-growth areas like oncology, targeting $50 billion in oncology sales by 2030 through R&D and strategic M&A. This strategic pivot, alongside its consistent financial performance and 63-year dividend growth, aims to drive faster growth and enhance shareholder value.

Analysis

Johnson & Johnson reported robust third-quarter financial results, with sales increasing nearly 7% to $24 billion and adjusted net income jumping almost 16% to $6.8 billion year-over-year. The company demonstrated strong financial health, generating $14.2 billion in free cash flow year-to-date, comfortably covering its $9.3 billion in dividend payments, and maintaining a pristine AAA bond rating with $19 billion in cash against $46 billion in debt. This performance reinforces its status as a Dividend King, having increased its dividend for 63 consecutive years, currently yielding 2.7%.

The company raised its full-year sales outlook to $93.7 billion (5.7% growth at midpoint) while maintaining its adjusted EPS growth outlook at 8.7% to $10.85 per share. A key strategic move involves separating its orthopedics business to sharpen focus on six priority growth areas, including oncology and immunology, aiming for faster growth and higher margins post-separation. This follows the successful blueprint of its Kenvue spin-off.

J&J is targeting an ambitious $50 billion in oncology sales by 2030, supported by over $10 billion in R&D investment year-to-date and strategic M&A, exemplified by the $2 billion Ambrx acquisition and reported talks for Protagonist Therapeutics. These investments, alongside a commitment to a strong balance sheet and continued dividend increases, underscore the company's strategy to drive shareholder value through innovation and focused growth.

Key Decisions for Investors

• Consider Johnson & Johnson for long-term, dividend-focused portfolios given its consistent dividend growth, strong financial profile, and strategic pivot towards higher-growth segments.
• Monitor the execution and financial impact of the planned orthopedics business separation, as this restructuring is intended to enhance overall growth and margin profiles.
• Evaluate the company's progress towards its $50 billion oncology sales target by 2030, as successful execution in this segment will be a significant driver of future revenue and earnings growth.